Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDanielle M. BranderKRKerry A. RogersDSDeborah M. Stephens

Discussion

Loading...

Member takes

Overview

Phase 1 trial found rocbrutinib shows 78.3% ORR in relapsed/refractory CLL, indicating potential in resistant cases.

Key Points

  • This research examines the effects of rocbrutinib on patients with relapsed/refractory CLL previously exposed to BTK and Bcl-2 inhibitors.
  • Multicenter phase 1 dose escalation study of rocbrutinib monotherapy
  • Involvement of patients with R/R B-cell malignancies
  • Calculation of overall response rate (ORR) including complete and partial responses.
  • ORR in patients post-BTKi is 78.3% with a median duration of treatment of 22.4 months.
  • Estimated median progression-free survival is 28.1 months with a 95% confidence interval.
  • Adverse events were mostly low grade, with 40.5% experiencing diarrhea and 35.7% experiencing cough.

Cite This Study

Brander et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d050https://doi.org/10.1182/blood-2025-87
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)2025 · 3 citations
  2. 2Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study2025
  3. 3Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial2025 · 1 citations
  4. 4Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 7 citations
  5. 5Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations